Orum Therapeutics Inc (475830)

Currency in KRW
63,200
-4,700(-6.92%)
Closed·
475830 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
62,20068,900
52 wk Range
16,930146,600
Key Statistics
Bid/Ask
63,100.00 / 63,200.00
Prev. Close
67,900
Open
67,200
Day's Range
62,200-68,900
52 wk Range
16,930-146,600
Volume
225.12K
Average Volume (3m)
249.83K
1-Year Change
254.6577%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
475830 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Orum Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Mar 19, 2026
EPS / Forecast
-752.83 / --
Revenue / Forecast
558.17K / --
EPS Revisions
Last 90 days

475830 Income Statement

Compare 475830 to Peers and Sector

Metrics to compare
475830
Peers
Sector
Relationship
P/E Ratio
−30.0x−27.4x−0.5x
PEG Ratio
0.06−0.570.00
Price/Book
12.2x2.8x2.6x
Price / LTM Sales
70,873.6x13.3x3.0x
Upside (Analyst Target)
-51.0%58.6%
Fair Value Upside
Unlock5.4%10.2%Unlock

Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases in South Korea and the United States. The company develops ORM-6151, which is in Phase I clinical trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes; ORM-1153, which is in pre-clinical trial for the treatment of acute myeloid leukemia and hematologic malignancies; and ORM-1023, which is in pre-clinical trial for the treatment of small cell lung cancer and neuroendocrine tumor. It is also involved in the development of multiple programs for the treatment of solid tumors and immunology and inflammation; and E3 Ligase-DAC adaptor, an adaptor linker platform that conjugates protein degraders to antibodies and enables E3 ligase-based DACs. The company was founded in 2016 and is headquartered in Daejeon, South Korea.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
524.63K2.44%35.62B
Other Institutional Investors
10.19M47.36%691.78B
Public Companies & Retail Investors
10.80M50.20%733.35B
Total
21.51M100.00%1.46T

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Vanguard STAR Funds - Vanguard Total International Stock ETF0.65%139,5039,472,254
Vanguard Tax-Managed Funds - Vanguard FTSE Developed Markets ETF0.44%93,7306,364,267

People Also Watch

251,000
062040
+8.42%
67,600
083650
-16.13%
104,800
080220
+2.24%
132,800
141080
+2.79%
349,000
196170
+3.56%

FAQ

What Is the Orum Therapeutics (475830) Stock Price Today?

The Orum Therapeutics stock price today is 63,200 KRW.

What Stock Exchange Does Orum Therapeutics Trade On?

Orum Therapeutics is listed and trades on the KOSDAQ.

What Is the Stock Symbol for Orum Therapeutics?

The stock symbol for Orum Therapeutics is "475830."

What Is the Orum Therapeutics Market Cap?

As of today, Orum Therapeutics market cap is 1.36T KRW.

What Is Orum Therapeutics's Earnings Per Share (TTM)?

The Orum Therapeutics EPS (TTM) is -2,264.

From a Technical Analysis Perspective, Is 475830 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Orum Therapeutics Stock Split?

Orum Therapeutics has split 0 times.

What is the current trading status of Orum Therapeutics (475830)?

As of Jun 15, 2026, Orum Therapeutics (475830) is trading at a price of 63,200 KRW, with a previous close of 67,900 KRW. The stock has fluctuated within a day range of 62,200 KRW to 68,900 KRW, while its 52-week range spans from 16,930 KRW to 146,600 KRW.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.